Paragraph IV Proceedings. With respect to any notification provided by a Third Party to BI or Zealand Pharma under 21 U.S.C. § 355 (j)(2)(B) with respect to Zealand Pharma Patents, Selected Zealand Pharma Patents or Collaboration Patents that are listed for a Product on the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations”, or equivalent actions in other countries (each a “Paragraph IV Proceeding”), the following shall apply:
Appears in 4 contracts
Samples: License and Collaboration Agreement (Zealand Pharma a/S), License and Collaboration Agreement (Zealand Pharma a/S), License and Collaboration Agreement (Zealand Pharma a/S)
